Pre-exposure Prophylaxis Uptake, Adherence, and Persistence: A Narrative Review of Interventions in the US

被引:44
作者
Garrison, Lindsey E. [1 ]
Haberer, Jessica E. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Ctr Global Hlth, 125 Nashua St,Suite 722, Boston, MA 02114 USA
[2] Harvard Med Sch, Dept Med, Boston, MA USA
关键词
ANTIRETROVIRAL PROPHYLAXIS; HIV-INFECTION; IMPROVE ADHERENCE; PREP ADHERENCE; LIFE-STEPS; MEN; PREVENTION; TENOFOVIR; SEX; STIGMA;
D O I
10.1016/j.amepre.2021.04.036
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Since 2012, HIV pre-exposure prophylaxis (PrEP) has been available to prevent HIV transmission; yet, uptake, adherence, and persistence to PrEP have been suboptimal. This narrative review examines the latest interventions and programs to improve all 3 stages of PrEP adherence and reviews ongoing studies to promote effective PrEP use. From 2017 to 2020, a total of 20 studies analyzed different individual- and structural-level approaches to increase PrEP adherence, including behavior change interventions, technology-based interventions (e.g., short message service messages and mobile applications), and alternate delivery strategies (e.g., pharmacy-based PrEP, integration with other services, and home delivery). Most published interventions involved men who have sex with men, although 3 assessed women (2 transgender, 1 cisgender). Randomized, controlled data support 3 behavioral change interventions and 1 technology-based intervention. Alternate delivery strategies seem promising, although more robust study designs are generally needed. In addition, data on the alignment of ongoing HIV risk and PrEP persistence (i.e., prevention-effective adherence) were limited. The authors also identified 20 ongoing studies that are promoting PrEP adherence. Future work should be inclusive of all at-risk groups in the U.S., including African American and Latinx heterosexual populations and people who inject drugs. Proven and promising approaches may work well in combination and may also need to be adapted with the introduction of long-acting pre-exposure prophylaxis formulations. Collectively, this body of work indicates considerable progress toward understanding the role PrEP adherence will play in Ending the HIV Epidemic in the U.S. that will be bolstered by the outcomes of ongoing trials. (C) 2021 American Journal of Preventive Medicine. Published by Elsevier Inc.
引用
收藏
页码:S73 / S86
页数:14
相关论文
共 65 条
[1]   Effectiveness of short message services and voice call interventions for antiretroviral therapy adherence and other outcomes: A systematic review and meta-analysis [J].
Amankwaa, Isaac ;
Boateng, Daniel ;
Quansah, Dan Yedu ;
Akuoko, Cynthia Pomaa ;
Evans, Catrin .
PLOS ONE, 2018, 13 (09)
[2]   Integrated Next Step Counseling (iNSC) for Sexual Health and PrEP Use Among Young Men Who Have Sex with Men: Implementation and Observations from ATN110/113 [J].
Amico, K. Rivet ;
Miller, Jessica ;
Balthazar, Christopher ;
Serrano, Pedro Alonso ;
Brothers, Jennifer ;
Zollweg, Sarah ;
Hosek, Sybil .
AIDS AND BEHAVIOR, 2019, 23 (07) :1812-1823
[3]   Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men [J].
Anderson, Peter L. ;
Glidden, David V. ;
Liu, Albert ;
Buchbinder, Susan ;
Lama, Javier R. ;
Vicente Guanira, Juan ;
McMahan, Vanessa ;
Bushman, Lane R. ;
Casapia, Martin ;
Montoya-Herrera, Orlando ;
Veloso, Valdilea G. ;
Mayer, Kenneth H. ;
Chariyalertsak, Suwat ;
Schechter, Mauro ;
Bekker, Linda-Gail ;
Kallas, Esper Georges ;
Grant, Robert M. .
SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (151)
[4]  
[Anonymous], Compendium of evidence-based interventions and best practices for HIV prevention. iText: evidence-informed for PrEP medication adherence/persistence
[5]  
[Anonymous], US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States-2021 Update: a clinical practice guideline
[6]  
[Anonymous], Compendium of evidence-based interventions and best practices for HIV prevention. Life-steps for PrEP: evidence-informed for PrEP medication adherence/persistence
[7]  
[Anonymous], 2017, P C RETROVIRUSES OPP
[8]   Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women [J].
Baeten, J. M. ;
Donnell, D. ;
Ndase, P. ;
Mugo, N. R. ;
Campbell, J. D. ;
Wangisi, J. ;
Tappero, J. W. ;
Bukusi, E. A. ;
Cohen, C. R. ;
Katabira, E. ;
Ronald, A. ;
Tumwesigye, E. ;
Were, E. ;
Fife, K. H. ;
Kiarie, J. ;
Farquhar, C. ;
John-Stewart, G. ;
Kakia, A. ;
Odoyo, J. ;
Mucunguzi, A. ;
Nakku-Joloba, E. ;
Twesigye, R. ;
Ngure, K. ;
Apaka, C. ;
Tamooh, H. ;
Gabona, F. ;
Mujugira, A. ;
Panteleeff, D. ;
Thomas, K. K. ;
Kidoguchi, L. ;
Krows, M. ;
Revall, J. ;
Morrison, S. ;
Haugen, H. ;
Emmanuel-Ogier, M. ;
Ondrejcek, L. ;
Coombs, R. W. ;
Frenkel, L. ;
Hendrix, C. ;
Bumpus, N. N. ;
Bangsberg, D. ;
Haberer, J. E. ;
Stevens, W. S. ;
Lingappa, J. R. ;
Celum, C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (05) :399-410
[9]   Qualitative accounts of PrEP discontinuation from the general population in Eswatini [J].
Barnighausen, Kate ;
Geldsetzer, Pascal ;
Matse, Sindy ;
Hettema, Anita ;
Hughey, Allison B. ;
Dlamini, Phiwa ;
Mavuso, Mxolisi ;
Fakudze, David ;
Kahn, Kathleen ;
Baernighausen, Till ;
McMahon, Shannon A. .
CULTURE HEALTH & SEXUALITY, 2021, 23 (09) :1198-1214
[10]   Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals [J].
Beymer, Matthew R. ;
Holloway, Ian W. ;
Pulsipher, Craig ;
Landovitz, Raphael J. .
CURRENT HIV/AIDS REPORTS, 2019, 16 (04) :349-358